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OBJECTIVES: Patient adherence with hypertension therapy is a leading cause for
uncontrolled blood pressure in the United States. The Anti-hypertensive Adher-
ence Survey (aHA Survey) was developed as a patient self-reported assessment of
therapy adherence. This study reports the psychometric properties and construct
validity of the tool. METHODS: The aHA Survey was administered to hypertensive
patients in a cross-sectional, non-interventional multisite study. The aHA Survey
comprises 25 items organized within six domains: Knowledge (9 items), Medical
Acceptance (3 items), Compliance (6 items), Finance (1 item), Willingness to
Change (4 items) and Depression (2 items). The aHA scoring algorithm assigns
points and designates intervention prompts based on patient’s responses to indi-
vidual items across each domain. Construct validity of the aHA Survey was evalu-
ated using an extension of the 1-parameter Rasch model for polytomous response
data when the items within a domain have unique rating domains and recall
periods, the Partial Credit Model. Unidimensionality was evaluated for the full
instrument and related scoring using goodness-of–fit statistics with an expected
range between 0.60-1.40. Reliability of the scores was assessed using the Rasch
person reliability estimate and the internal structure evaluated using Principal
Components Analysis. RESULTS: A total of 273 patients ere included in the study
(50.9% male, 89.7% Caucasian). Item fit was acceptable for all items on the aHA
Survey. The overall reliability for aHA Survey was moderate to high (alpha  0.84)
and 33.3% of the underlying variance in adherence was measured by the items on
the instrument. CONCLUSIONS: This study demonstrates the utility of measuring
a multi-dimensional phenomenon such as adherence in patient’s hypertensive
therapy using a brief 25-item assessment. The current items and related scoring
algorithm indicate good construct validity and reliability; which is imperative for
clinical utility. Validation against real-world data will be considered in the next
phase of research.
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OBJECTIVES: Gout is one of the most common inflammatory arthritides; it is com-
monly managed in primary care in the UK and has been associated with poor
cardiovascular (CV) outcomes. Allopurinol use has been associated with improved
outcomes, particularly at a higher dose (600mg/day); however, published studies
have shown that prescribed doses in the UK are 300mg or less. Adherence to allo-
purinol has not been well evaluated in the UK; we estimate the impact of adherence
to allopurinol on CV in gout patients in the UK. METHODS: The Health Improve-
ment Network (THIN) database from 1990 to 2009 was examined; patients aged 18
were identified using Read and drug codes. The CV-related outcomes were myo-
cardial infarction (MI), heart failure, stroke, peripheral thrombosis, angina and
coronary artery bypass. Adherence was measured using proportion of days covered
(PDC). Descriptive statistics were calculated and Kaplan-Meir survival curves were
constructed for different levels of adherence (PDC in quartiles). Analyses were
performed in a subset of patients that experienced a particular CV event during the
observation period. RESULTS:A total of 91,665 gout patients were identified, 39,747
of which were prescribed allopurinol; of these, 9% had MI, 18% had heart failure,
15% had stroke, 4% had thrombosis, 16% had angina and 5% had coronary artery
bypass. Mean PDC in patients prescribed with allopurinol was 0.72 (SD0.28).
Higher PDC was associated with increased survival time in all CV events except for
angina. PDC  0.75 resulted in substantially greater survival time. High adherence
has the greatest impact in MI and coronary artery bypass. CONCLUSIONS: Greater
adherence to allopurinol appears to be associated with better CV outcome in all
conditions except angina. A more profound effect in PDC higher than 0.75 suggests
that high adherence is needed to achieve clinical benefit.
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OBJECTIVES: To evaluate treatment persistence in patients receiving fixed-dose
combinations or unfixed combinations with olmesartan medoxomil (OLM) or val-
sartan (VAL) for hypertension treatment in Germany. METHODS: This retrospec-
tive study analyzed prescription data collected by general practitioners, using a
longitudinal database, the German IMS Disease Analyzer (DA). The DA database
was searched for patients with hypertension (ICD-10 code I10) who were initiated
on OLM or VAL in double combinations with hydrochlorothiazide (HCT) or amlo-
dipine (AML) in the period 09/2008 to 08/2009 with a follow-up of at least 12 months.
Persistence was defined as proportion of patients who remained on their initially
prescribed therapy at 1 year. RESULTS: In total, 2882 patients were eligible for
analysis (1079 patients receiving OLM, thereof 75.2% with fixed-dose combinations;
1803 patients receiving VAL, thereof 88.5% with fixed combinations). 12 months
after the first prescription, more patients receiving OLM stayed on their initial
therapy compared to VAL: unfixed combination with AML 27.4% vs. 25.2%; fixed-
dose combination with AML 47.3% vs. 44.6%; unfixed combination with HCT 25.0%
vs. 13.7%; fixed-dose combination with HCT 44.6% vs. 39.6%. Mean duration of
persistence in patients receiving OLM compared to VAL group was: 183.6 [SD 163.5]
days vs. 181.2 [SD 159.8] days in unfixed combinations with AML; 235.7 [SD 167.8]
days vs. 234.6 [SD 165.0] days in fixed-dose combinations with AML; 184.0 [SD 155.4]
days vs. 123.4 [SD 138.9] days in unfixed combinations with HCT; 228.5 [SD 167.8]
days vs. 222.9 [SD 165.6] days in fixed-dose combinations with HCT.
CONCLUSIONS:Overall, findings based on real-life prescription data suggest better
patient persistence with unfixed and fixed-dose OLM combinations compared to
respective VAL combinations. In terms of persistance not all angiotensin receptor
blockers perform equal rather hint at patient-individual treatment. Further re-
search is needed to confirm these first results.
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OBJECTIVES: Patient adherence with prevention and treatment of chronic disease
is challenging. Communication theory has potential to improve effectiveness of
interventions to improve adherence. This study used Theory of Reasoned Action
(TRA) variables to examine behavioral, normative injunctive and control beliefs
associated with statin adherence; association of beliefs with intentions and adher-
ence; and variation among subgroups (sex, race, treatment duration, primary vs.
secondary prevention). METHODS: Cardiology and primary care academic health
system patients prescribed statins January 2007 to December 2009 (n101,492).
Elicitation Study: Semi-structured telephone interviews (n40). Mail Survey: Ran-
dom sample stratified by race and prior CVD events (N1829). Causal path regres-
sion coefficients were compared using multi-group structural equation modeling,
stratified by race, gender and age. RESULTS: Elicitation Study: Respondents per-
ceived statin therapy as beneficial and reported supportive social norms and good
self-efficacy. Adherence failure was associated primarily with inability to act on
intentions rather than lack of intention. Mail Survey: Response50.2%; (53% male,
61% CVD event; 39% AA; mean age 65). AAs & women had lower intentions; AA
lower self-efficacy and normative pressure; older respondents higher self-efficacy;
secondary prevention higher normative pressure and behavioral beliefs. Males
were higher and those with perceived side effects lower for all three reasoned
action intention predictors. Non-event group: R2 intentions0.41. Adherence was
associated most strongly with attitudes. AAs were lower on all reasoned action
intention predictors. CVD event group: R2 Intentions0.20. Adherence was most
strongly associated with attitudes and self-efficacy. No socio-demographic variable
differentiated among intention predictors. CONCLUSIONS: Intentions and adher-
ence were associated most strongly with behavioral, normative and self-efficacy
beliefs and differed across demographic and prior event subgroups, suggesting
potential to improve adherence using targeted messages based on reasoned action
variables addressing subgroup specific beliefs. Intentions and adherence were pre-
dicted better for primary than secondary prevention, suggesting greater potential
for TRA-based targeted messages for those without a previous CVD event.
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OBJECTIVES: The study aimed to assess predictors of medication adherence in a
hypertensive population of Pakistan. METHODS: This descriptive study was
shaped as a questionnaire-based cross sectional analysis. A prevalence based sam-
ple of 385 hypertensive patients was selected from 2 tertiary care hospitals. Hyper-
tension Fact Questionnaire (HFQ), Drug Attitude Inventory (DAI-10) and European
Quality of Life scale (EQ-5D) were used for data collection. Demographic and dis-
ease related information was also taken into account. SPSS versus 16.0 was used to
compute descriptive analysis of patients’ demographic and disease related infor-
mation. The factors that were significantly associated with adherence were further
assessed by binary logistic regression analysis. The analysis included only those
parameters with p value0.25 in Chi-square analysis. The power of independently
related parameters and predictive models were expressed as odds ratio (OR) with
95% confidence intervals (CI). The statistical significance was set at 0.05. RESULTS:
The mean age (SD) of the patients was 39.02 (6.596), with 68.8% males. The mean
SD duration of hypertension was 3.010.939 years. Forty percent (n154) had bach-
elor level of education with 34.8% (n134) were working in private sector. The
mean EQ-5D descriptive score was calculated 0.46740.28444 and EQ-Vas score
63.976.621. Mean knowledge and adherence scores were 8.03  0.42 and -1.74
2.154 respectively. The created model showed a significant goodness of fit as the
Omnibus Test of Model Coefficient was highly significant (Chi square 10.983, p
0.027, df  4). Knowledge score had significant association (adjusted OR 1.159,
95% CI 1.004 – 1.339, P 0.001) with medication adherence. CONCLUSIONS: From
the results of our study, it is concluded that improved knowledge towards hyper-
tension can result in better medication adherence. Patient education must be for-
malized and acknowledged as an official part of the health care system.
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